NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
1.480
+0.090 (6.47%)
Mar 31, 2025, 2:23 PM EDT - Market open

Company Description

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.

The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).

Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD.

The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist.

It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America.

NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLS Pharmaceutics AG
NLS Pharmaceutics AG logo
Country Switzerland
Founded 2015
IPO Date Jan 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Alexander Zwyer

Contact Details

Address:
The Circle 6
Zurich, 8058
Switzerland
Phone 41 44 512 21 50
Website nlspharma.com

Stock Details

Ticker Symbol NLSP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.15
CIK Code 0001783036
CUSIP Number H57830103
ISIN Number CH0523961370
SIC Code 2834

Key Executives

Name Position
Alexander Zwyer M.B.A. Co-Founder, Chief Executive Officer and Director
Dr. Eric Konofal M.D., Ph.D. Co-Founder and Chief Scientific Officer
Nicole Fernandez-McGovern CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 425 Filing
Mar 31, 2025 6-K Report of foreign issuer
Mar 10, 2025 425 Filing
Mar 10, 2025 6-K Report of foreign issuer
Mar 3, 2025 F-4/A Filing
Feb 27, 2025 6-K Report of foreign issuer
Feb 25, 2025 425 Filing
Feb 25, 2025 6-K Report of foreign issuer
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 10, 2025 F-3 Filing